Physicochemical Properties
| Molecular Formula | C21H17CLN4O2 |
| Molecular Weight | 392.84 |
| Exact Mass | 392.104 |
| CAS # | 2305052-86-0 |
| PubChem CID | 138506238 |
| Appearance | Off-white to light yellow solid powder |
| LogP | 3.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 6 |
| Heavy Atom Count | 28 |
| Complexity | 553 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | MHPBTJANPDDCPH-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C21H17ClN4O2/c1-2-20(27)26(14-16-9-6-10-19(22)24-16)17-11-12-18(23-13-17)21(28)25-15-7-4-3-5-8-15/h2-13H,1,14H2,(H,25,28) |
| Chemical Name | 5-[(6-chloropyridin-2-yl)methyl-prop-2-enoylamino]-N-phenylpyridine-2-carboxamide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | TMEM173 activation is inhibited by BPK-25 (10 μM; 5 hours) through the cyclic dinucleotide ligand cGAMP [2]. As indicated by a >50% decrease in IκBα phosphorylation, BPK-25 (10 μM; 24 hours) suppresses nuclear factor of activated T cells (NFAT) activation and NF-κB activation [1]. T cell NFATc2 expression is likewise decreased by BPK-25 (10 μM; 4 hours) [1]. In a concentration- and time-dependent manner, BPK-25 (0.1, 1, 5, 10, 20 μM; 24 hours) promotes the substantial and selective decrease of many proteins in the nucleosome remodeling and deacetylation (NuRD) complex. The mRNA expression of BPK-25 did not alter in a similar way [1]. BPK-25-ctrl, the non-electrophilic propionamide analog of BPK-25, does not change NuRD complex proteins in T cells or limit T cell activation [1]. |
| References | [1]. Ekaterina V Vinogradova, et al. An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells. Cell. 2020 Aug 20;182(4):1009-1026.e29. |
Solubility Data
| Solubility (In Vitro) | DMSO: 150 mg/mL (381.83 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 3.75 mg/mL (9.55 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.75 mg/mL (9.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 3.75 mg/mL (9.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5456 mL | 12.7278 mL | 25.4557 mL | |
| 5 mM | 0.5091 mL | 2.5456 mL | 5.0911 mL | |
| 10 mM | 0.2546 mL | 1.2728 mL | 2.5456 mL |